scorecardresearchDr Reddys Laboratories Share Price 4,359.05

Dr Reddys Laboratories

BSE: 500124 | NSE: DRREDDY | ISIN: INE089A01023 | SECTOR: Biotechnology & Drugs

4,359.05 -40.85 (-0.93%)

01 Jul 2022, 05:13 (IST)
  • Open

    4,370.05
  • High

    4,375.35
  • Low

    4,290.00
  • Prev Close

    4,399.90
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    -
  • Volume

    3.94K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
4359.05
  • 4,290.00
  • Intraday
  • 4,375.35
4359.05
  • 3,655.00
  • 52 Wk H/L
  • 5,613.65
4359.05
  • 3,959.95
  • DPR
  • 4,839.85

Key Metrics

- Mkt. Cap.

V

Volatility %

Market Sentiment

  • Moderately Positive
B

Beta -

Genie Says

Influencer Count

20

Financials

  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)
52 Week
High
52 Week
Low
Market Cap.
(Cr)

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    Simple Moving Averages

    DaysBSENSE

    Dr Reddys Laboratories is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    Company Description

    • Large Cap
    • Automobiles
    • BSE

      500124
    • NSE

      DRREDDY
    • ISIN

      INE089A01023

    Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company’s segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

    Company Officers

    • Satish Reddy

      Chairman of the Board
    • G.V. Prasad

      Co-Chairman of the Board, Managing Director
    • Erez Israeli

      Chief Executive Officer
    • Parag Agarwal

      Chief Financial Officer
    • Patrick Aghanian

      Chief Executive Officer, European Generics
    • Marc Kikuchi

      Chief Executive Officer, North America Generics
    • M. Ramana

      Chief Executive Officer, Branded Markets (India and Emerging Markets)
    • Archana Bhaskar

      Chief Human Resource Officer
    • Mukesh Rathi

      Chief Digital and Information Officer
    • K. Randhir Singh

      Chief Compliance Officer, Company Secretary